Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

NHPig Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models

Coordinator
Ludwig-Maximilians-Universitaet Muenchen, Germany
Runs
1 October 2024 to 30 September 2029
Status
Running
EU funding
€8.5m
Total cost
€17.5m
Partners
32 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101165643

What the project is doing

In the project's own words, from its summary on CORDIS.

NHPig is an Innovative Health Initiative (IHI) project based on the public-private partnership of the European Union and Europe’s health industries. Its objective is to expand, share and implement biological knowledge of mini-/micropig models with the aim to reduce non-human primates (NHPs) in non-clinical safety studies. The transnational consortium includes experts in porcine medical models, veterinary pathology, computational animal science, non-clinical science, OMICs profiling, new approach methods (NAMs), as well as bioinformatics and artificial intelligence.

NHPig will i) characterise humanised minipigs, micropigs and tailored disease models, including systematic biobanking, multi-OMICs profiling, and state-of-the-art imaging modalities; ii) develop, validate and implement biosensors, medical devices, and ‘intelligent’ animal housing for automated data collection and analysis in minipig safety studies; iii) fill significant knowledge gaps in the (patho)physiology of the porcine immune system; iv) validate known toxicity and efficacy biomarkers and discover novel biomarker candidates for non-clinical safety assessment; v) overcome the shortage of laboratory tools and reagents, such as validated antibodies; vi) gain experience in using mini-/micropigs for safety testing of biologicals and new therapeutic modalities; vii) Investigate in vitro to in vivo extrapolation of liver and kidney toxicity in pigs and NHP/humans to provide a comparative link to human new approach methodologies (NAMs); and viii) provide a publicly available database and IT platform for compiling, integrating and analysing existing data in NHPs/humans with data in mini-/micropig models (existing data and data generated within the NHPig programme).

The establishment of a regulatory advisory board and an ethics- and animal welfare advisory board will expedite regulatory interactions and ensure compliance with the 3R principles. NHPig will generate the scientific basis for de-selection of NHPs in non-clinical safety assessment, which is an ethical requirement and also imperative according to EU legislation.

Topics

Who is involved

OrganisationCityCountryRole
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyCoordinator
Veterinaermedizinische Universitaet WienWienAustriaParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Universiteit AntwerpenAntwerpenBelgiumParticipant
Eidgenoessisches Departement Des InnernBernSwitzerlandAssociatedpartner
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Ustav Zivocisne Fyziologie a Genetiky Av Cr V.v.i.LibechovCzechiaParticipant
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Boehringer Ingelheim InternationalgmbhIngelheimGermanyParticipant
Boehringer Ingelheim Pharma GmbH &co KgIngelheimGermanyAssociatedpartner
Merck Healthcare KgaaDarmstadtGermanyAssociatedpartner
Merck Kommanditgesellschaft Auf AktienDarmstadtGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyAssociatedpartner
Technische Universitaet MuenchenMuenchenGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Ellegaard Gottingen Minipigs ASDalmoseDenmarkParticipant
H. Lundbeck ASValbyDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Charles River Laboratories France Safety AssessmentSaint-Germain-NuellesFranceParticipant
EtisenseLyonFranceParticipant
Sanofi-Aventis Recherche & DeveloppementGentillyFranceParticipant
Biotalentum Tudasfejleszto KftGoedoelloHungaryParticipant
Mediso Orvosi Berendezes Fejleszto es Szerviz Kft.BudapestHungaryParticipant
Avantea SRLCremonaItalyParticipant
Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A.Colleretto GiacosaItalyAssociatedpartner
Karolinska InstitutetStockholmSwedenParticipant
Glaxosmithkline Research & Development LimitedLondonUnited KingdomParticipant
Labcorp Early Development Laboratories LimitedHarrogateUnited KingdomParticipant
Breakthrough T1dNew YorkUnited StatesParticipant
Sanofi US Services Inc.Cambridge, MassachusettsUnited StatesAssociatedpartner
Verisim Life IncSan FranciscoUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI